Moneycontrol PRO
HomeNewsBusinessDr Reddy's launches generic cancer drug in India

Dr Reddy's launches generic cancer drug in India

Patent on Dasatinib is owned by Bristol-Myers-Squibb. The Indian patent has expired on April 12, 2020.

April 13, 2020 / 12:44 IST
     
     
    26 Aug, 2025 12:21
    Volume
    Todays L/H
    More

    Dr Reddy's Laboratories on Monday said it has launched blood cancer drug Invista in the country. The company's product is a formulation of Dasatinib that is bioequivalent to the innovator brand, Dr Reddy's Laboratories said in a statement.

    Patent on Dasatinib is owned by Bristol-Myers-Squibb. The Indian patent has expired on April 12, 2020.

    Also readCoronavirus News India LIVE Updates

    Invista, which is available in strengths of 50, 70 and 100 mg tablets, is indicated for the treatment of primarily Chronic Myeloid Leukemia (CML).

    CML is a type of blood-cell cancer that begins in the bone marrow.

    The median age of the patients in India is a decade earlier than the west, and every year about nine thousand new patients are diagnosed in the country.

    Also readIn pics | Stocks in the news: HDFC, Dr Reddy’s Labs, Gulf Oil Lubricants, SRF, Godrej Consumer, CSB Bank

    "The development and launch of Invista is a significant step forward in improving access to medicines at an affordable price for CML patients in India," Dr Reddy's Laboratories CEO, Branded Markets (India and Emerging Markets), M V Ramana said.

    PTI
    first published: Apr 13, 2020 12:35 pm

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347